List of Wound Healing Companies in United States - 65

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Amnio Technology is an industry leader in the development and manufacture of amnion-derived technologies. Amnio Technology manufactures high-quality, amnion-derived technologies for clinical use.

Aposcience AG aspires to improve the health of patients in need of regenerative medicine by commercially exploiting the therapeutic potential of secretomes derived from white blood cells (PBMCs) isolated from peripheral blood. PBMCs are currently a waste product of all blood transfusion units.

Applied Biologics is a fully-integrated life sciences company providing research, product development, manufacturing and distribution of medical technologies. Since 2010, Applied Biologics has been dedicated to providing innovative biologic solutions to deliver optimal patient outcomes. The entire Applied Biologics team is dedicated to each other and the company's success. The executive team, medical advisory board, scientific advisory board, researchers, product development team, manufacturing technicians, distribution team, sales representatives, support team, reimbursement department and administrative staff are professionals and leaders in their fields. Together, we continue to strive for excellence and being a leader in delivering biological solutions to treat a growing list of medical indications.

Our mission is to decrease the quantity and severity of infections that cause human suffering through the creation and development of novel, targeted, antimicrobial therapies. Our lead technology, Veriox®, is a first-of-it's-kind, proprietary peracid/hydrogen peroxide based non-systemic antimicrobial agent. Our vision is to improve societal health by protecting humans, animals and the environment from harmful viruses and chemical agents. ArmiClenz™ (EPA registered disinfectant spray, cleaner/odor control) and ArmiVet™ (Topical wound, rash and hot spot care for animals) are two exciting new consumer brands that support our vision.

Auration Biotech is developing novel therapeutics for ear, nose and throat diseases. The company is based in San Mateo, California and has a focus on developing transformational platform of advanced therapies to cure blindness.

Beeken Biomedical is an medical device company focused on the development, licensing and commercialization of wound care products. Beeken Biomedical introduces innovative and cost-effective technologies that rapidly stop bleeding and help protect wounds from infection. Beeken Biomedical is committed to improve solutions in wound care for healthcare professionals and consumers.

Developing new drugs under FDA regulation for hypoxia brain and heart ischemia and viral infection like coronavirus and influenza.

BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.

Bravida is redefining what's possible in wound care and infection prevention, with a portfolio of transformative products and technologies that are clinically proven to deliver uncompromising freedom and protection

Claris Bio works to improve lives by uniting unmet needs in ophthalmology with robust science and data-driven decision-making. The company is focused on developing topical formulation technology designed to treat orphan ophthalmic disorders, such as neurotrophic keratitis, and cure corneal diseases.

Clene Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapeutics for neurodegenerative diseases. The company has a nanotechnology drug platform for the development of orally administered neurotherapeutic drugs. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson’s; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company’s products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; and NM-PtAu7, a gold-platinum CSN therapeutic. Clene Inc. is based in Salt Lake City, Utah.

Comparative Biosciences Inc., a Genesis Drug Discovery and Development (GD3) Company, a premier preclinical contract research organization (CRO) committed, for the last 20 years, to providing expert high-quality contract research services to all sectors of the biomedical community. Extensive experience in the biotechnology and pharmaceutical industries provides our staff with an exceptional track record in preclinical research and drug development capabilities. Our on-site histology laboratory offers routine histopathology, special stains, immunohistochemistry (IHC), plastics, GLP antibody tissue cross reactivity (TCR), and histomorphometry services with quick turn around times. We also have the benefit of having an on site board-certified pathologist for evaluation and reporting of all the histology work done here.

Coriell Life Sciences (CLS), an international leader in precision medicine, delivers DNA testing benefits that empower the most precise medical care, improve population health, and reduce healthcare costs. We work with retirement systems, pension funds, health plans, employers, public and private organizations, pharmacy benefit managers (PBMs), benefits brokers, and laboratories around the globe to eliminate needless risks, costs, and waste associated with trial-and-error prescribing. https://www.youtube.com/c/CoriellLifeSciences

Creative Peptides is specialized in the process development and the manufacturing of bioactive peptides. They offer custom peptide synthesis, process development, manufacturing as well as catalog products for customers in industry and research area.

Headquartered in Brooklyn, New York, Cresilon, Inc. is a privately-held medical device company focused on hemostatic technologies that improve wound care and advance the standard of medical treatments. For more information, visit Cresilon.com. We are always looking for dynamic people to join our team as we dive into a range of challenges at the forefront of science and technology—to learn more about our openings please visit https://cresilon.workable.com/.

Crown Aesthetics, the premier medical aesthetics company, is dedicated to helping leading plastic surgeons, dermatologists, and aesthetic physicians around the world grow their businesses. We do that by delivering dramatic results in rejuvenation and restoration. Our non-invasive innovations – SkinPen®, the first FDA-cleared microneedling device; the post-microneedling protocol Skinfuse® and the platelet-rich plasma system ProGen™ – act as "gateway" products that draw new consumers to practices. Based in Dallas, Texas, Crown Aesthetics sets industry standards for efficacy, safety, and innovation. As a result, our customers consistently deliver the best aesthetic care in the business. Learn more at CrownAesthetics.com.

Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The unique and proprietary technology owned by Dermaliq, called hyliQ, is designed to allow cutaneous drug delivery with unmatched bioavailability. The technology enables the development of superior, highly effective liquid drug products with exceptional cosmetic properties.

DermaRite manufactures cost-effective skin care, wound care, and nutritional supplements for healthcare facilities, including hospitals, nursing homes, hospice, and home care. Founded in 1995, DermaRite's state of the art manufacturing and warehousing facility is in North Bergen, New Jersey. With a distribution and sales network throughout the United States, facilities can be assured of fast, reliable service and personalized attention. DermaRite customers also receive access to a wide range of clinical and educational tools, making us one of the best values in the industry. DermaRite is an FDA and OSHA approved manufacturer.

Direct Biologics is a market-leading innovator in regenerative medicine.

At Elutia we’re pioneering the future of patient care. Our proprietary drug-eluting biomaterial platforms stand at the forefront of medical innovation.

Embody, Inc. is a commercial-stage company pioneering the next generation in collagen-based tendon and ligament healing for the fast-growing sports medicine market. Founded in 2014, the company is developing unique biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair.

ENCOLL CORP. is a medical devices company based out of 4576 ENTERPRISE STREET, FREMONT, California, United States.

Engineered Tissue Solutions (ETS) is an emerging wound care company, re-defining wound care with cutting-edge bioactive glass technology that reduces healing time, minimizes treatment costs and improves patient outcomes. Our flagship product, MIRRAGEN® Advanced Wound Matrix, is a next-generation intervention for wound healing. Using synthetic, absorbable bioactive glass fiber technology, MIRRAGEN accelerates healing, decreases wound area, reduces costs, and is safe and easy to use.

As a company, we are breathing new life into the regenerative therapeutics market. Our agile and highly experienced team works tirelessly to develop faster, better and easier ways to get our doctors and patients the products and services they need. Every day, we partner with the world's leading medical and scientific experts to drive innovation out of the laboratory and into the treatment room. At the same time, we transform the complexity of reimbursement into a process that's simple and clear for all. We are Evolution. We transform lives.

Femasys is a biomedical company focused on transforming women's healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc®, a first and only non-surgical product for permanent birth control and FemaSeed™, a first and only directed sperm delivery product for infertility treatment. Femasys' FemVue® product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician's office setting.

FibroBiologics is the world leader in cell therapy using fibroblasts to regenerate tissue and cure chronic diseases. Currently, FibroBiologics holds 150+ U.S. and international issued patents issued/pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, and Cancer. FibroBiologics represents the next generation of medical advancement in cell therapy.

We are a Colorado-based biomaterials company intentionally designing new materials to improve wound healing. Our materials are anti-inflammatory, prevent bacterial adhesion, and are capable of controlled drug delivery.

Heart Hugger is a medical devices company that specializes in post-operative care for cardiac and thoracic surgery patients, focusing on pain management through a unique device.

H.B. Fuller | Adhezion Biomedical, LLC is a medical device company focused on the development and commercialization of highly differentiated cyanoacrylate based surgical, wound management and infection prevention technologies. Founded in 2001, the company is based in Wyomissing, Pennsylvania. The vision of the Adhezion team is to redefine the way cyanoacrylate based surgical adhesives and sealants are used in medicine. Our mission is to provide technologies that achieve optimal patient outcomes. Adhezion currently is developing and commercializing cyanoacrylate‐based adhesives and sealants for use in both professional and consumer healthcare settings.

Imagine Pharma is a biotechnology company focused on three distinctive platforms: oral delivery, regenerative and therapeutics. Each platform has first-in-class programs that address multiple disease states in large underserved markets.

Imbed Biosciences Inc. is a privately held medical device company emerging as a leader in the development of advanced synthetic therapies for the treatment of surgical wounds, burns, chronic ulcers, and soft-tissue repair. Imbed has a portfolio of products commercially available, and in development, based on its patented Microlyte® technology. Imbed Biosciences is registered with U.S. FDA as a medical device manufacturer and maintains an ISO 13485 certified Quality Management System. For more information, please visit www.imbedbio.com, facebook.com/imbedbio, and follow @ImbedBio on twitter.

Jointechlabs is a regenerative medicine company that offers point-of-care medical devices enabling safe and cost-effective non-surgical treatments.

Weaving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse, but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing our innovative spirit and deep commitment to advancing the treatment of eye diseases. KALA BIO is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye. KALA BIO’s biologics-based investigational therapies utilize KALA BIO’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA BIO’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA BIO is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA BIO, please visit www.kalarx.com.

KeraNetics is the global leader in keratin science, purified, human-derived keratin manufacture, research and development for healthier wound healing KeraNetics provides physicians with new options to help patients by exploiting the properties of purified, human-derived keratin. KeraStat® Cream: Better management of radiation dermatitis (RD). KeraStat® Cream harnesses the power of keratin proteins to support the management of dry, light, and moderately exuding partial thickness skin wounds such as radiation dermatitis resulting from a fractionated radiotherapy regimen. FDA cleared and available in 1 oz. and 5 mL tubes. Rx only.

KitoTech Medical is a Seattle-based medical device company that has developed microMend PRO, a unique wound closure device. microMend PRO is a new wound closure device that is as effective as sutures and as fast and easy to apply as a bandage. It delivers superior clinical results and improved patient experience while reducing procedure costs. microMend PRO can close wounds up to 50 cm in length and is effective in closing all types of lacerations including those with jagged edges. Our products are used by medical personnel in emergency medicine, dermatology, surgeons, and more. Request a quote for your clinic today!

Developing novel serpin-based therapies for the treatment of fibrosis and fibroproliferative disorders.

Medcura, Inc. is a medical device company based in Riverdale, Maryland, founded in 2007. The company specializes in developing hemostatic products aimed at effective bleeding management and advanced wound care solutions for surgical, medical, and consumer markets. Medcura's primary focus is on creating and distributing hemostatic products that utilize a proprietary technology platform. Their offerings include LifeGel™, a flowable gel for surgical procedures; LifeFoam™, a hemostatic agent for traumatic wounds; and RapidSeal, an antibacterial first aid product. Other solutions include Triple R, Medcura Flex, and Surgicura, all designed to control bleeding and promote healing. These products leverage a modified chitosan biopolymer to enhance safety and efficacy. The company has received significant recognition, including five FDA clearances and two FDA Breakthrough Device Designations. Medcura has raised over $47 million in funding from various investors, including government agencies and private organizations.

MediCell Technologies (MCT) believes that stem cells can bring unique and exceptional value to health care.We forms Strategic Partnerships with industry and academia entities to facilitate and accelerate preclinical development of stem cell therapies. We are working to advance the field of stem cell applications. Progenitor Biologics®, LLC and AT Scientific, LLC are wholly owned subsidiaries of MediCell Technologies DefenAge® is a brand of Progenitor Biologics.

Since 1996, Minnetronix Medical has accelerated medical device breakthroughs as a design, development and manufacturing partner to leading device companies around the world. Today, through life-cycle efficiency, opportunity realization, and increased utility, the organization is creating value in key technology segments, including RF energy, fluid and gas management, optical systems, and stimulation and active wearables. From design and manufacturing services to whole product solutions, Minnetronix brings expansive industry insight and intentional technical acumen, delivering better medical devices to market, faster. Minnetronix is based in St. Paul, Minnesota. ​

MLM Biologics Inc. (MLM) is a Delaware C-Corp company founded on the modern interpretation of Gandhian Economic Principle of "More for Less for Many". The company utilizes their expertise in chemistry and biology of scaffolds, and a proprietary processing platform, to deliver evidence-based solutions for musculoskeletal and wound care problems.

MTI designs, manufactures, and sells surgery and exam chairs and tables, medical cabinetry, stools, and many related accessories for the Podiatry, Otolaryngology, Dermatology, Plastic Surgery, Oral Surgery, and Ophthalmology specialties. The continued challenge of combating rising healthcare costs and advances in ambulatory medical care has influenced MTI to develop an entire family of power chairs/tables, cabinetry, seating, and accessories to meet the needs of medical professionals and patients in order to help deliver and receive quality medical care at reasonable costs.

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low intensity acoustic technology. The company's patented technology allows for creation of miniature transducers that transmit low-frequency, low-intensity ultrasound through flexible material surfaces. This unique development may be utilized for a variety of medical requiring low cost therapeutic ultrasound applications. The company's patch based product diagnosis, PainShield®, carries an FDA clearance. NanoVibronix catheter based products include the CathbotTM . NanoVibronix Inc. is located in Elmsford, NY. Its subsidiary, NanoVibronix Ltd. is located in Nesher, Israel.

Noxsano is a wound care company dedicated to developing medical dressings that deliver bio-signaling molecules to enable effective treatment of acute and chronic wounds. Noxsano's patent pending technology has been shown in pre-clinical testing to restore normal wound healing to ischemic (chronic) wounds and accelerate the healing of acute and burn wounds

Nuo Therapeutics, Inc. is a biomedical company that develops and commercializes individualized wound care therapies that harness a patient’s innate regenerative ability to stimulate wound healing. The Company’s flagship product, Aurix is a biodynamic hematogel derived from the patient’s own platelets and plasma, which is used at the point-of-care to jumpstart the natural healing process in a broad range of chronic wounds, including diabetic foot ulcers, venous leg ulcers and pressure injuries.

Progenitec is a healthcare company that facilitates faster healing of chronic wounds through accurate and fast diagnosis.

Collagen Matrix is now Regenity Biosciences. Regenity Biosciences advances new frontiers in regenerative science, turning bioabsorbable materials into life-changing solutions. Sought after for our novel resorbable technologies and distinct approach to contract manufacturing and contract development, our team brings the urgency and vision to deliver breakthrough medtech solutions for medical technology and medical device manufacturers of all sizes. Company Background For more than 25 years, Regenity Biosciences has been transforming bioabsorbable materials into regenerative solutions to repair and regenerate tissue and bone we have since introduced numerous bioresorbable technologies with more than 71 product lines commercially available worldwide. Most recently, Regenity expanded its product portfolio to include versatile bioresorbable polymer technologies via the acquisition of Polyganics, which was the impetus behind the new name and brand direction. Regenity is headquartered in Paramus, New Jersey, with manufacturing locations in Oakland and Allendale, New Jersey and Groningen, the Netherlands. Mission & Values Every day, we work to make a material difference in the lives of patients. With people’s health on the line, it’s our duty to act with urgency and diligence. It is this collective ethos that drives us each day to push the boundaries of what’s possible in tissue repair and regeneration. Looking for a Career with Purpose? Join our team and work with us to develop life-changing products that help patients heal. Visit our website to learn more about what sets Regenity apart. www.Regenity.com CMIContact@CollagenMatrix.com

RevMedx is a start-up medical device company dedicated to bringing lifesaving products to the field of trauma medicine. Working under grants from the US Army, we are developing a line of wound dressings that will create a new standard for the treatment of traumatic hemorrhage—the leading cause of combat mortality. Currently our line of hemorrhage control products include: XSTAT, XGAUZE, AIRWRAP, SHARKBITE kit and TX2/TX3 Tourniquet Belts.

With our focus on improving patient outcomes with evidence-based healing solutions, Sanara MedTech Inc. develops, markets and distributes surgical, wound care and skin care products to physicians, hospitals, clinics and all post-acute care settings. We are constantly seeking long-term strategic partnerships with a focus on products that produce efficacious outcomes at a lower overall cost. Our primary products are sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech sells and distributes CellerateRX® Surgical Activated Collagen® Powder to the surgical market and BIAKŌS™ Antimicrobial Skin and Wound Cleanser, Irrigation Solution, and Wound Gel, HYCOL® Hydrolyzed Collagen, and PULSAR II™ Advanced Wound Irrigation System (AWI™) to the wound care market.

As an emerging leader in the development and commercialization of energy transfer technology, SANUWAVE® presents products that help expedite wound healing on a cellular level. SANUWAVE's easy-to-use ENERGY FIRST® product portfolio works to help heal some of the most difficult, stalled, or hard-to-heal wounds by activating the body's normal regenerative process using an assortment of energy waves, from shockwaves to ultrasound. SANUWAVE values patient comfort and the importance of wound healing, recognizing its' value to not only improve patient quality of life but to help avoid further complications that could lead to amputation or even lives lost. SANUWAVE's minimally to completely non-invasive technologies can help wounds heal with little to no pain or discomfort. Most treatments can be done in under ten minutes, however, results may vary depending on wound size and patient response to treatment. The UltraMIST System delivers low-frequency ultrasound to the treatment site using a noncontact fluid (e.g., saline). MIST Systems produce a low energy ultrasound-generated mist used to promote wound healing through wound cleansing and maintenance debridement by the removal of fibrin, yellow slough, tissue exudates, and bacteria. The MOA includes control of inflammation, augmentation of local tissue perfusion, wound bacteria and bacterial biofilm reduction, increased angiogenesis, and more. The dermaPACE System is an advanced wound care device that utilizes pulsed acoustic cellular expression (PACE®) technology, a proprietary form of focused, extracorporeal shockwaves. It is the first shockwave system to be FDA-cleared for the treatment of diabetic foot ulcers (DFU). For general inquiries, please email: info@sanuwave.com

We provide comprehensive treatment for acute and chronic wounds across all patient care settings, from the latest advances in chronic wound treatment and prevention to clinical research and hyperbaric medicine.

SigmaGraft®, based in Fullerton, California, USA, collaborates with the world's leading clinicians and researchers to innovate products and build clinical experience. Our products are registered and sold worldwide, and they include bone grafting products for bone regeneration, membrane products for tissue regeneration, and more.

Smith & Nephew plc is a healthcare company that specializes in medical devices for orthopedics, wound care, and surgical equipment.

SomaGenics is a privately held biotech company with offices and laboratories located in Santa Cruz, CA. We specialize in small RNA technologies, including innovative RNAi-based therapeutics using sshRNA molecules, and diagnostics/biomarker detection (NGS, quantitative PCR) of small or fragmented RNA, including microRNA.

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by "Seeing the Unknown®" with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of changing the current standard of care in the future, DeepView® is expected to provide faster and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2023 Sales: $20.5 billion ● Industry: Medical Instruments & Supplies ● Employees: 52,000 worldwide ● 40 years of sales growth leading up to 2020 ● 44+ Manufacturing and R&D Locations Worldwide ● $1.4 billion spent on research and development in 2023 ● ~12,900 patents owned globally in 2023 ● Products sold in ~75 countries ● Fortune 500 Company ● 7 consecutive years as one of Fortune's World's Best Workplaces Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296

Simplifying your journey to closure with our collagen + honey advanced wound care products. #woundcareforall Sweetbio is a commercial-ready, medical device company with novel, honey-incorporated wound care products (FDA cleared May 2019).

A forward-thinking, medical technology company dedicated to developing life-saving products and therapies that encourage healing, reduce complications of tissue damage and inflammation, prevent infection by drug-resistant bacteria and remove the biofilms in which they thrive. We use the best of nature to solve important, real-time problems.

Telios Pharma, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in developing therapies for mast cell-mediated inflammatory diseases. Founded in 1993, the company focuses on small-molecule drugs and has a team of 51 to 100 employees. Its annual revenue is estimated between $10 million and $25 million. The company's pipeline includes innovative Bruton’s tyrosine kinase (BTK) inhibitors. Notable candidates are TL-925, a topical eye drop for dry eye disease currently in Phase 2 trials, and M-7583, an oral BTK inhibitor for primary myelofibrosis. TL-925 has shown promising results, providing rapid relief from symptoms and significant improvements in clinical measures. Telios Pharma aims to address significant unmet needs in both dry eye disease and myelofibrosis, targeting markets with limited existing therapies.

Tricol Biomedical, Inc. is a medical device company based in Portland, Oregon, established in 2001. Originally known as HemCon, the company has become a leader in advanced acute wound care and hemostatic solutions. Tricol Biomedical is committed to improving hemostatic and wound care management through innovative products and technologies, with a mission centered on saving lives. The company offers a variety of hemostatic solutions, including its proprietary Chitosan products like HemCon PRO, which are designed for rapid hemorrhage control. Their product range includes items for trauma management, procedural care, and consumer self-care, catering to the needs of healthcare professionals, military personnel, and individuals seeking effective wound care solutions. Tricol Biomedical continues to focus on enhancing care standards in the medical field.

It’s the Ventris focus on quality, donor selection, tissue recover, and processing protocols that sets us apart. The company is dedicated to providing products that adhere to the strictest current tissue banking and processing standards, with the ultimate goal of an exceptional outcome for the patient. Our line of human allograft products is regulated by the FDA Center for Biologics Evaluation and Research (CBER), which regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps). Ventris adheres to Current Good Tissue Practices, focusing extensively on donor eligibility and the recovery process. Ventris Allograft products are regulated under 21 CFR Part 1270 and 21 CFR Part 1271 and Section 361 of the Public Health Services Act.

Vomaris Innovations, Inc. is a medical device company based in Tempe, Arizona, that focuses on bioelectric technology for infection control and wound healing. Founded in 2004, the company operates globally, with its products registered in nine countries and over one million wounds treated using its technology. The company's patented V.Dox™ Technology utilizes moisture-activated microcell batteries embedded in a substrate. This technology generates a wireless electric field that mimics the body's natural healing process, targeting bacterial biofilms and reducing infection risk. Vomaris offers products such as the Procellera® Antimicrobial Wound Dressing, which is validated in numerous peer-reviewed publications, and the PowerHeal™ Antibacterial Bioelectric Bandages, available over-the-counter for superficial wounds. Their solutions are applicable in various medical fields, including chronic and acute wound care, surgical incisions, and veterinary medicine.

Xequel Bio, Inc. is a clinical stage biopharmaceutical company advancing its proprietary aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) technology platform to develop drugs that will enable physicians to better manage a variety of indications involving inflammation and the body's response to injury. aCT1 is a patented new chemical entity currently in development for multiple indications. The Company's lead clinical programs include Granexin® gel in dermatology and iNexinTM ophthalmic solution in ophthalmology. The Company also has ongoing preclinical research in pulmonology.

Zurex Pharma is a specialty pharma and medical technology company based in Middleton, Wisconsin.

ZZ Biotech is a clinical stage company developing innovative biologic treatments for ischemic stroke, neurological diseases and wound healing applications including the treatment of diabetic foot ulcers. ZZ Biotech was incepted in 2006 to focus on the development of 3K3A-APC, a novel second-generation variant of a naturally occurring human protein licensed from The Scripps Research Institute. ZZ Biotech’s experimental drug 3K3A-APC is a genetically engineered variant of human activated protein C (APC), a serine protease optimized for human therapeutic use. ZZ Biotech completed RHAPSODY, a placebo-controlled multicenter Phase 2 clinical trial of 3K3A-APC in patients suffering from acute ischemic stroke. The study was supported and funded by the NIH’s National Institute of Neurological Disorder and Stroke (NINDS) through a pair of NeuroNEXT grants. The Phase 2 study evaluated safety, tolerability and vasculoprotective activity of 3K3A-APC when given after tissue plasminogen activator (tPA), mechanical thrombectomy, or both, in patients who have experienced moderate to severe ischemic stroke. 3K3A-APC was deemed safe and well-tolerated at all dose levels tested. Furthermore, intracerebral bleeding was substantially reduced in patients treated with 3K3A-APC. In June 2020 the FDA designated the investigation of the ZZ Biotech’s experimental drug 3K3A-APC for the treatment of acute ischemic stroke as a Fast Track development program. In May of 2022 the NINDS awarded $4 million of a grant budgeted to total approximately $30 million to researchers at the Keck School of Medicine of USC to conduct a pivotal Phase 3 clinical trial in acute ischemic stroke using 3K3A-APC. The multinational trial, to be run in the NIH StrokeNet, will commence in 2023. ZZ Biotech also has active clinical programs in ALS and wound healing. 3K3A-APC’s unique multi-modal mechanism of action is well suited to address both of these areas of great unmet medical need.